|
Mölnlycke® Health Care, a global leader in MedTech, today announces its largest investment to date: a €115 million expansion of its wound care manufacturing capacity in Brunswick, Maine, USA.
This move is a key part of Mölnlycke’s ongoing localisation strategy, aimed at producing products where they are sold. It addresses increasing US customer demand and underscores Mölnlycke's commitment to growth, customer centricity and sustainability.
Zlatko Rihter, CEO of Mölnlycke, says, "This expansion strengthens our US presence and our mission to free patients and caregivers from the burden of wounds. With increased manufacturing capacity, we’re ready to meet the growing needs of our customers and take our US growth to the next level."
Over the next five years, Mölnlycke will invest around €115 million to secure the supply of Mölnlycke's life-changing wound care products in the world’s largest medtech market. The expansion will create new job opportunities, increasing the local workforce by 10%, as well as engaging local contractors.
By expanding its US manufacturing capacity, Mölnlycke will strengthen its supply chain resilience, mitigate risk exposure and ensure the timely delivery of products to healthcare providers and patients across the US and beyond.
The state-of-the-art facility will support Mölnlycke’s long-term sustainability goals by utilising renewable energy sources like wind and solar power and reducing climate impact through streamlined logistics.
Additionally, the expansion will integrate cutting-edge machinery and technical equipment from US suppliers to enable high quality and efficient production of advanced wound care products.
Chris Biddle, General Manager US Manufacturing, Wound Care, Mölnlycke, says, “This expansion is a very big deal and the result of over a year’s hard work. Besides creating new jobs, it will drive workforce development and bring technological advancements. It’s a win for Mölnlycke, for the local community and for patients. We’re excited about the positive impact it will have locally in Maine and across the broader US healthcare landscape.”
| 
